Refine by
Insulin Production Articles & Analysis
16 news found
This peptide-based API acts as an agonist of the glucagon-like peptide-1 (GLP-1) receptor. By enhancing insulin production, Semaglutide enables exploration into methods of regulating blood sugar levels, making it a focal point for researchers investigating metabolic regulation. ...
Nasaldrugdeliveryblog.com opens lines of communication between drug delivery researchers, device manufacturers. The first blog to address issues related to nasal drug delivery formulation, research, delivery, and devices was launched by Kurve Technology, Inc., a leading developer of nasal drug delivery devices. The blog - http://www.nasaldrugdeliveryblog.com - invites scientists, researchers ...
(the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced an update on the development of its initial insulin pump product. ...
(the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today provided an update on its insulin pump product. ...
The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly ...
The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly ...
“In our first trial with intralymphatically administered Diamyd, DIAGNODE-1, all three individuals who received a fourth injection preserved their own insulin production over at least one additional year, which is ...
Preliminary (5 months) data on safety and endogenous insulin production have been published in the scientific journal Frontiers in Endocrinology. ...
Although research categorizes LADA as autoimmune diabetes, the disease is still in most cases treated according to the guidelines for type 2 diabetes. LADA patients are usually not insulin dependent at diagnosis, but for most patients, insulin therapy is required within a few years of diagnosis. ...
The clinical course appears positive with all 14 individuals remaining insulin-independent after 12 months of follow-up. The endogenous insulin production, measured as mixed-meal stimulated C-peptide, declined on average only 10% over 12 months. ...
Of particular interest for Diamyd Medical will be the advancement of C-peptide preservation (a biomarker for the body’s own insulin production) as a primary endpoint for regulatory approval. Another focus for Diamyd Medical will include developing Continuous Glucose Monitoring (CGM) as an endpoint fit for regulatory approval. ...
The abstract posted today details results from the Phase 1/2 clinical trial, demonstrating VX-880 can restore insulin production and glucose control in T1D. Data will be updated and additional information will be presented at the conference. ...
The aim of the trial is to evaluate the safety of a booster (fourth/fifth) injection with Diamyd® and the effect on the immun system and the endogenous insulin production. The patients will be followed for 12 months after injection.The trial will be conducted at the Clincal Resarch Unit at the University Hospital in Linköping. ...
Patient 2 Islet cell function was evaluated at baseline and at Day 90 after VX-880 infusion using a Mixed Meal Tolerance Test (MMTT) with quantification of C-peptide levels, a direct marker for endogenous insulin production. At baseline prior to VX-880 infusion, fasting and stimulated C-peptide levels were undetectable, indicating no endogenous ...
The lawsuit was filed by a number of shareholders and alleged that Novo Nordisk had made misleading statements and did not make appropriate disclosures regarding its sales of insulin products in the US. The original claim was for a total amount of DKK 11,785,192,218. ...
Viatris and Biocon Biologics Ltd. launched their interchangeable Semglee® products (insulin glargine-yfgn) last month, which are the first, and currently the only, interchangeable biosimilars to Lantus®, providing more affordable options for the millions of Americans living with diabetes. ...
ByBiocon